Published on 10 Aug 2023 on Zacks via Yahoo Finance
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -833.33%. A quarter ago, it was expected that this eye drug developer would post a loss of $0.58 per share when it actually produced a loss of $0.71, delivering a surprise of -22.41%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.